3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
12
Colorectal Neoplasms
9
Neoplasm Metastasis
4
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
2
Solid Tumors Harboring a BRAF V600 Mutation
1
Skin Neoplasms
1
Skin Diseases
1
Recurrence
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Brain Neoplasms
1
Advanced BRAF Mutant Cancers
1
Interventions
Gemcitabine
7
Leucovorin
6
Irinotecan
6
Fluorouracil
6
130-nm albumin-bound paclitaxel
6
Albumin-Bound Paclitaxel
5
napabucasin
4
Capecitabine
4
Paclitaxel
3
Oxaliplatin
3
Ocoxin
3
Bevacizumab
3
pembrolizumab
2
entinostat
2
Sorafenib
2
Imatinib Mesylate
2
Everolimus
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
5,10-methylenetetrahydrofolic acid
2
tislelizumab
1
spartalizumab
1
pralsetinib
1
palbociclib
1
irinotecan sucrosofate
1
halofantrine
1
guadecitabine
1
fludarabine
1
ficlatuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Digestive System Neoplasms
×
encorafenib
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled